Morgan Stanley analyst Drew Ranieri downgraded Integra LifeSciences to Underweight from Equal Weight with an unchanged price target of $44. The analyst sees limited signs of a growth or profitability inflection for the company, and therefore a lack of upside over the next 6-12 months. As a result, the firm sees other opportunities within its coverage universe.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IART:
- Integra LifeSciences price target lowered to $60 from $65 at JMP Securities
- Integra LifeSciences sees Q3 adjusted EPS 76c-80c, consensus 84c
- Integra LifeSciences lowers FY23 EPS view to $3.10-$3.18 from $3.43-$3.51
- Integra LifeSciences reports Q2 adjusted EPS 71c, consensus 57c
- Integra LifeSciences Reports Second Quarter 2023 Financial Results